منابع مشابه
Mevalonate Metabolism in Immuno-Oncology
Immuno-oncology not only refers to the multifaceted relationship between our immune system and a developing cancer but also includes therapeutic approaches that harness the body's immune system to fight cancer. The recognition that metabolic reprogramming governs immunity was a key finding with important implications for immuno-oncology. In this review, we want to explore how activation and dif...
متن کاملThe immuno-oncology framework
Developers of cancer immunotherapy have struggled for decades to achieve clinical success in using the patient's immune system to treat cancer. In the absence of a defined development paradigm for immunotherapies, conventional criteria established for chemotherapy were applied to these agents. This article summarizes the recent lessons for development of agents in the immunotherapy space, descr...
متن کاملStatistical issues and challenges in immuno-oncology
BACKGROUND The development of immuno-oncologic agents poses unique challenges, namely that both efficacy and safety profiles differ from previously characterized cytotoxic and pathway-specific agents. In addition, exponential distribution is usually assumed in study designs with time-to-event endpoints such as overall survival or progression-free survival. This assumption might lead to wrong es...
متن کاملPrimer on immuno-oncology and immune response.
Advances in the understanding of the immunogenicity of tumors have provided the basis for immuno-oncology, the development of immunotherapeutic agents that augment the patient's antitumor immunity and disrupt the immune-regulatory circuits that allow tumors to evade the immune system. Two immunomodulatory agents recently have been introduced for the treatment of malignancy: sipuleucel-T and ipi...
متن کاملNanobiotix establishes promising preclinical proof-of-concept in Immuno Oncology
Immuno-oncology works by boosting patients’ immune systems to recognise and attack tumours and therefore, kill the cancer. The approach is very efficient for a limited number of patients whose tumors have the ability to provoke an immune response i.e. they have a natural and sufficient immunogenicity, and are referred to as ‘hot’ tumors. However, in many patients, the tumours are ‘cold’ and the...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Immuno-Oncology Technology
سال: 2021
ISSN: 2590-0188
DOI: 10.1016/j.iotech.2021.100028